COVID-19 and the liver: A 2021 update

Catherine W. Spearman, Alessio Aghemo, Luca Valenti, Mark W. Sonderup

Research output: Contribution to journalArticlepeer-review

Abstract

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China and has since resulted in a global pandemic in excess of 165 million reported infections and 3.4 million attributable deaths. COVID-19 is primarily a respiratory illness, which may be complicated by pneumonia and acute respiratory distress syndrome. SARS-CoV-2 is also responsible for numerous extrapulmonary manifestations involving the haematologic, cardiovascular, renal, gastrointestinal and hepatobiliary, endocrinologic, neurologic, ophthalmologic and dermatologic systems. This review will discuss the pathophysiology of COVID-19; focusing on the mechanisms and outcomes of liver injury associated with COVID-19; its impact on chronic liver disease (CLD); management of CLD during the COVID-19 pandemic and the long-term impact of COVID-19 on CLD.

Original languageEnglish
Pages (from-to)1988-1998
JournalLiver International
Volume41
Issue number9
DOIs
Publication statusPublished - 2021

Keywords

  • COVID-19
  • liver disease
  • liver injury
  • liver transplantation
  • SARS-CoV-2

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'COVID-19 and the liver: A 2021 update'. Together they form a unique fingerprint.

Cite this